Morepen’s margin expands as revenue growth outpaces costs
Consolidated operating margin rose 2.01 percentage points sequentially, though it remained below the Healthcare peer median as management outlined further expansion.
Filed 27 Oct 2026, 13:31 IST · Morepen Laboratories Ltd (MOREPENLAB)
Key takeaways
- Consolidated revenue grew 30.94% sequentially to Rs 746.5 cr, while expenses grew 27.85%, lifting operating profit 49.18%.
- Operating margin widened by 2.01 percentage points to 16.49% as revenue grew faster than expenses, but remained 6.23 percentage points below the 22.72% Healthcare peer median.
- Net profit rose 57.61% sequentially to Rs 88.89 cr, helped by a 0.66 percentage-point decline in the tax rate, while other income contributed 7.46% of pre-tax profit.
Price around the results
Revenue growth created operating leverage
Morepen Laboratories’ consolidated revenue increased 30.94% sequentially to Rs 746.5 cr, while expenses rose 27.85% to Rs 623.39 cr. The resulting gap between revenue and cost growth lifted operating profit 49.18% to Rs 123.12 cr, ahead of the 30.94% revenue increase. Net profit grew 57.61% to Rs 88.89 cr, with EPS rising to Rs 1.62.
Margin improved, with some support below operating profit
Operating margin expanded by 2.01 percentage points to 16.49% because expenses grew more slowly than revenue. Interest expense still increased 7.23% and depreciation rose 20.60% sequentially, partly absorbing the operating improvement. The tax rate fell by 0.66 percentage points to 23.72%, while other income accounted for 7.46% of pre-tax profit, so the net-profit increase was not driven solely by operations.
Margin remains near the low end of Healthcare peers
Among 12 Healthcare companies that had reported the same quarter, Morepen’s 16.49% operating margin was 6.23 percentage points below the 22.72% sector median and ranked second from the bottom. The available trend shows an improvement from the 14.48% margin in Q1FY27, but does not establish a longer multi-quarter direction.
Management links earnings to API and CDMO expansion
Management said the company’s transformation plan involves greater investment in scale, innovation capability and reinvestment. The presentation reported API and CDMO commissioning alongside an H1 CDMO mandate, and said Q2FY27 earnings strength enables the next phase of expansion. These comments provide the company’s stated explanation for its expansion focus rather than a forecast of future results.
Q2FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 | Q1FY27 | QoQ |
|---|---|---|---|
| Revenue | ₹747 cr | ₹570 cr | +30.94% |
| Other income | ₹9 cr | ₹5 cr | +65.84% |
| Expenses | ₹623 cr | ₹488 cr | +27.85% |
| Operating profit | ₹123 cr | ₹83 cr | +49.18% |
| Operating margin (%) | 16.49% | 14.48% | — |
| Interest | ₹5 cr | ₹5 cr | +7.23% |
| Depreciation | ₹10 cr | ₹8 cr | +20.60% |
| Profit before tax | ₹117 cr | ₹75 cr | +56.26% |
| Tax | ₹28 cr | ₹18 cr | +52.09% |
| Net profit | ₹89 cr | ₹56 cr | +57.61% |
| EPS (₹) | ₹1.62 | ₹1.03 | +57.28% |
Operating margin of 16.49% compares with a Healthcare sector median of 22.72% across 12 peers that have reported Q2FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Expansion
- The transformation flywheel includes larger reinvestment.
- The presentation reports API and CDMO commissioning alongside an H1 CDMO mandate.
- The company says Q2 FY27 earnings strength enables the next phase of expansion.
New initiatives
- The transformation flywheel includes stronger scale and innovation capability investment.
What to watch
- Whether consolidated operating margin holds above 16.49% after the Q2FY27 expansion.
- Whether the gap to the 22.72% Healthcare peer median narrows.
- Whether other income remains close to 7.46% of pre-tax profit.